Effects of pestle needle on nerve conduction velocity and inflammatory injury in patients with diabetic peripheral neuropathy

Wang, Fang; Liao, Shunqi; Wen, Jinyu; Han, Wei; Wang, Yao; Weng, XiMei; Wu, Rong; Huang, Ya‐Ling

doi:10.53388/tmr20220119257

Cited by 4 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 2 summarizes the general characteristics of 16 studies [15,[35][36][37][38][39][40][41][42][43][44][45][46][47][48][49] with 1035 participants included in this dose-response meta-analysis. In brief, the included RCTs had parallel designs and were published from March 1997 to October 2020.…”

Section: Characteristics Of Primary Trials Included In the Dose-respo...mentioning

confidence: 99%

“…In brief, the included RCTs had parallel designs and were published from March 1997 to October 2020. Of the 16 included studies, eight studies were conducted in Asia [36, 40-43, 45, 48, 50], five were conducted in Europe [15,35,39,47,51], while three were conducted in the US [37,44,46]. All trials included adult patients with type 2 diabetes.…”

Section: Characteristics Of Primary Trials Included In the Dose-respo...mentioning

confidence: 99%

“…The daily doses of oral ALA ranged from 200 mg/d [40] to 1200 mg/d [36,43]. The duration of diabetes ranged from 2 [37,42] to over 20 [46] years. No study reported on the change of medication during the intervention period.…”

Section: Characteristics Of Primary Trials Included In the Dose-respo...mentioning

confidence: 99%

“…Pooled results from the random-effects model on seven RCTs with 563 participants [15,36,37,39,43,46,50] showed that each 500 mg/d increase in ALA supplementation can result in a significant reduction in BMI (MD: -1.07 kg/m 2 ; 95% CI: -1.90 to -0.25, p = 0.01) with substantial heterogeneity between the eligible studies (I 2 = 94.7%, P heterogeneity < 0.0001) (Table 3, Supplementary Figure 3). In the sensitivity analysis, we found that this association was influenced by the results of the study by Okanovic and colleagues [15].…”

Section: Effect Of Ala Supplementation On Weight Lossmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose–response meta-analysis of randomized trials

Jibril

Jayedi

Shab‐Bidar

2022

Endocrine Connections

View full text Add to dashboard Cite

Objective: To examine the dose-dependent influence of oral ALA supplementation on cardiometabolic risk factors in type 2 diabetes (T2D) patients. Design: We followed instructions outlined in the Cochrane Handbook for Systematic Reviews of Interventions and the Grading of Recommendations, Assessment, Development, and Evaluation Handbook to conduct our systematic review. The protocol of the study was registered in PROSPERO (CRD42021260587). Method: We searched PubMed, Scopus, and Web of Science to May 2021 for trials of oral ALA supplementation in adults with T2D. The primary outcomes were HbA1c, weight loss, and low-density lipoprotein cholesterol (LDL-C). Secondary outcomes included fasting plasma glucose (FPG), triglyceride, C-reactive protein, and blood pressure. We conducted a random-effects dose-response meta-analysis to calculate the mean difference (MD) and 95%CI for each 500 mg/d oral ALA supplementation. Non-linear dose-response meta-analyses were also conducted. Results: We included 16 trials with 1035 patients. Each 500 mg/d increase in oral ALA supplementation significantly reduced HbA1c, body weight, CRP, FPG, and TG. Dose-response meta-analyses indicated a linear decrement in body weight at ALA supplementation of more than 600 mg/d (mean difference 600 mg/d: -0.30 kg, 95%CI: -0.04, -0.57). A relatively J-shaped effect was seen for HbA1c (mean difference: -0.32%, 95%CI: -0.45, -0.18). Levels of FPG and LDL decreased up to 600 mg/d ALA intake. The point estimates of the certainty of evidence were below minimal clinically important difference thresholds for all outcomes. Conclusion: Despite significant improvements, the effects of oral ALA supplementation on cardiometabolic risk factors in T2D patients were not clinically important.

show abstract

Section: Characteristics Of Primary Trials Included In the Dose-respo...mentioning

confidence: 99%

Section: Characteristics Of Primary Trials Included In the Dose-respo...mentioning

confidence: 99%

Section: Characteristics Of Primary Trials Included In the Dose-respo...mentioning

confidence: 99%

Section: Effect Of Ala Supplementation On Weight Lossmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose–response meta-analysis of randomized trials

Jibril

Jayedi

Shab‐Bidar

2022

Endocrine Connections

View full text Add to dashboard Cite

show abstract

“…The major component of the mechanism and pathogenies of PNI involves oxidative stress and inflammation that exacerbates neural damages and plays a negative role in the regeneration process [ 109 ]. Experimental evidence at the preclinical level has demonstrated that inhibiting oxidative stress could help improve functional recovery by accelerating the repair processes [ 110 , 111 , 112 , 113 , 114 ].…”

Section: Oxidative Stress and Neurodegenerative Diseasesmentioning

confidence: 99%

Antioxidant Therapy in Oxidative Stress-Induced Neurodegenerative Diseases: Role of Nanoparticle-Based Drug Delivery Systems in Clinical Translation

et al. 2022

View full text Add to dashboard Cite

Free radicals are formed as a part of normal metabolic activities but are neutralized by the endogenous antioxidants present in cells/tissue, thus maintaining the redox balance. This redox balance is disrupted in certain neuropathophysiological conditions, causing oxidative stress, which is implicated in several progressive neurodegenerative diseases. Following neuronal injury, secondary injury progression is also caused by excessive production of free radicals. Highly reactive free radicals, mainly the reactive oxygen species (ROS) and reactive nitrogen species (RNS), damage the cell membrane, proteins, and DNA, which triggers a self-propagating inflammatory cascade of degenerative events. Dysfunctional mitochondria under oxidative stress conditions are considered a key mediator in progressive neurodegeneration. Exogenous delivery of antioxidants holds promise to alleviate oxidative stress to regain the redox balance. In this regard, natural and synthetic antioxidants have been evaluated. Despite promising results in preclinical studies, clinical translation of antioxidants as a therapy to treat neurodegenerative diseases remains elusive. The issues could be their low bioavailability, instability, limited transport to the target tissue, and/or poor antioxidant capacity, requiring repeated and high dosing, which cannot be administered to humans because of dose-limiting toxicity. Our laboratory is investigating nanoparticle-mediated delivery of antioxidant enzymes to address some of the above issues. Apart from being endogenous, the main advantage of antioxidant enzymes is their catalytic mechanism of action; hence, they are significantly more effective at lower doses in detoxifying the deleterious effects of free radicals than nonenzymatic antioxidants. This review provides a comprehensive analysis of the potential of antioxidant therapy, challenges in their clinical translation, and the role nanoparticles/drug delivery systems could play in addressing these challenges.

show abstract

The cellular and molecular targets of natural products against metabolic disorders: a translational approach to reach the bedside

Shen,

Yang,

Yang

et al. 2024

MedComm

View full text Add to dashboard Cite

Metabolic disorders, including obesity, dyslipidemia, diabetes, nonalcoholic fatty liver disease, and metabolic syndrome, are characterized by insulin resistance, abnormalities in circulating cholesterol and lipid profiles, and hypertension. The most common pathophysiologies of metabolic disorders are glucose/lipid metabolism dysregulation, insulin resistance, inflammatory response, and oxidative stress. Although several agents have been approved for the treatment of metabolic disorders, there is still a strong demand for more efficacious drugs with less side effects. Natural products have been critical sources of drug research and discovery for decades. However, the usefulness of bioactive natural products is often limited by incomplete understanding of their direct cellular targets. In this review, we highlight the current understanding of the established and emerging molecular mechanisms of metabolic disorders. We further summarize the therapeutic effects and underlying mechanisms of natural products on metabolic disorders, with highlights on their direct cellular targets, which are mainly implicated in the regulation of glucose/lipid metabolism, insulin resistance, metabolic inflammation, and oxidative stress. Finally, this review also covers the clinical studies of natural products in metabolic disorders. These progresses are expected to facilitate the application of these natural products and their derivatives in the development of novel drugs against metabolic disorders.

show abstract

Effects of pestle needle on nerve conduction velocity and inflammatory injury in patients with diabetic peripheral neuropathy

Cited by 4 publications

References 0 publications

Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose–response meta-analysis of randomized trials

Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose–response meta-analysis of randomized trials

Antioxidant Therapy in Oxidative Stress-Induced Neurodegenerative Diseases: Role of Nanoparticle-Based Drug Delivery Systems in Clinical Translation

The cellular and molecular targets of natural products against metabolic disorders: a translational approach to reach the bedside

Contact Info

Product

Resources

About